In recent years, new drugs have appeared, anti-TNF (biotherapy).
If, before them, the main aim of the treatments was to reduce or eliminate the clinical symptoms of the disease, the anti-TNF could intervene directly on the lesions and modify the natural history of the disease, and thus allow more ambitious objectives. .
They are effective in both attack treatment and maintenance treatment. They are active on intestinal lesions of the disease that they are able to heal quickly, but also on the ano-perineal and extra-intestinal lesions.
Two anti-TNF alpha drugs are currently marketed in France. It is infliximab and adalimumab. They act by neutralizing a pro-inflammatory substance, TNF (tumor necrosis factor). The anti-TNF alpha drugs are produced to block the inflammatory action of cytokines TNF alpha, present in very large numbers during IBD, especially in case of thrust.They can fight against inflammatory reactions, especially during the Crohn's disease.
Surgery may be considered when other treatments are not sufficient. In case of fistula, for example, or complete obstruction of the digestive tract or perforated ulcer. Surgery does not prevent the progression of the disease, but it can considerably relieve the patient and sometimes reset the "counters to zero". The injured part can be completely removed.
It all depends on the location of the lesions. It is performed during stenosis, abscess, inflammatory masses or symptomatic fistulas. Colorectal lesions can be treated by segmental colectomy, that is with the removal of the injured part of the colon.
In video: Bacteria against IBD?
Will recent research work finally offer effective treatment to patients with ulcerative ulcerative colitis or Crohn's disease? The answers in video ...Want to react, share your experience or ask a question? Appointment in our FORUMS Belly and digestion or A doctor answers you !